[go: up one dir, main page]

DE60309887D1 - Kombination von einem aromatasehemmer mit einem bisphosphonat - Google Patents

Kombination von einem aromatasehemmer mit einem bisphosphonat

Info

Publication number
DE60309887D1
DE60309887D1 DE60309887T DE60309887T DE60309887D1 DE 60309887 D1 DE60309887 D1 DE 60309887D1 DE 60309887 T DE60309887 T DE 60309887T DE 60309887 T DE60309887 T DE 60309887T DE 60309887 D1 DE60309887 D1 DE 60309887D1
Authority
DE
Germany
Prior art keywords
aromatase
bisphosphonate
disease
combination
aromatase inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60309887T
Other languages
English (en)
Other versions
DE60309887T2 (de
Inventor
S Bhatnagar
Brent Evans
Andreas Gasser
Jonathan Green
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0217636A external-priority patent/GB0217636D0/en
Application filed by Novartis AG filed Critical Novartis AG
Application granted granted Critical
Publication of DE60309887D1 publication Critical patent/DE60309887D1/de
Publication of DE60309887T2 publication Critical patent/DE60309887T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
DE60309887T 2002-07-30 2003-07-29 Kombination von einem aromatasehemmer mit einem bisphosphonat Expired - Lifetime DE60309887T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0217636 2002-07-30
GB0217636A GB0217636D0 (en) 2002-07-30 2002-07-30 Organic compounds
US42548202P 2002-11-12 2002-11-12
US425482P 2002-11-12
PCT/EP2003/008377 WO2004012728A1 (en) 2002-07-30 2003-07-29 Combination of an aromatase inhibitor with a bisphosphonate

Publications (2)

Publication Number Publication Date
DE60309887D1 true DE60309887D1 (de) 2007-01-04
DE60309887T2 DE60309887T2 (de) 2007-05-16

Family

ID=31497252

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60309887T Expired - Lifetime DE60309887T2 (de) 2002-07-30 2003-07-29 Kombination von einem aromatasehemmer mit einem bisphosphonat

Country Status (12)

Country Link
US (1) US20060069067A1 (de)
EP (1) EP1534265B1 (de)
JP (1) JP2011057706A (de)
CN (1) CN100593401C (de)
AT (1) ATE345790T1 (de)
AU (1) AU2003250190A1 (de)
BR (1) BR0313081A (de)
CA (1) CA2494345C (de)
DE (1) DE60309887T2 (de)
ES (1) ES2276119T3 (de)
PT (1) PT1534265E (de)
WO (1) WO2004012728A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0328040D0 (en) * 2003-12-03 2004-01-07 Coleman Robert E Pharmaceutical uses of bisphosphonates
WO2005117864A1 (en) * 2004-05-28 2005-12-15 Astrazeneca Ab Combination product comprising anastrozole and a dual prenyl transferase inhibitor
EP1945224B1 (de) 2005-10-19 2012-05-02 Chavah Pty Ltd Verringerung der nebenwirkungen von aromatase-hemmern zur behandlung von brustkrebs
AU2015336929B2 (en) 2014-10-22 2021-03-18 Havah Therapeutics Pty Ltd Methods of reducing mammographic breast density and/or breast cancer risk
JP2018534291A (ja) 2015-10-22 2018-11-22 ハバフ セラピューティクス ピーティーワイ エルティーディー マンモグラフィ乳房密度及び／又は乳癌のリスクを低下させる方法
CN109641874A (zh) 2016-05-10 2019-04-16 C4医药公司 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
WO2017197051A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Amine-linked c3-glutarimide degronimers for target protein degradation
EP3454856B1 (de) 2016-05-10 2024-09-11 C4 Therapeutics, Inc. Heterocyclische degronimere für zielproteinabbau
CN110769822A (zh) 2017-06-20 2020-02-07 C4医药公司 用于蛋白降解的n/o-连接的降解决定子和降解决定子体
CN111372585A (zh) 2017-11-16 2020-07-03 C4医药公司 用于靶蛋白降解的降解剂和降解决定子
JP2021519337A (ja) 2018-03-26 2021-08-10 シー４ セラピューティクス， インコーポレイテッド Ｉｋａｒｏｓの分解のためのセレブロン結合剤
EP3781156A4 (de) 2018-04-16 2022-05-18 C4 Therapeutics, Inc. Spirocyclische verbindungen
US11524014B2 (en) 2019-06-03 2022-12-13 Havah Therapeutics Pty Ltd. Pharmaceutical formulations and systems for delivery of an androgenic agent and an aromatase inhibitor with sustained multi-phasic release profiles and methods of use
WO2023014590A1 (en) * 2021-08-05 2023-02-09 Celanese Eva Performance Polymers Llc Implantable medical device for the delivery of bisphosphonate

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4617307A (en) * 1984-06-20 1986-10-14 Ciba-Geigy Corporation Substituted imidazo[1,5-A]pyridine derivatives as aromatase inhibitors
DE3428524A1 (de) * 1984-08-02 1986-02-13 Boehringer Mannheim Gmbh, 6800 Mannheim Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
US4749713A (en) * 1986-03-07 1988-06-07 Ciba-Geigy Corporation Alpha-heterocycle substituted tolunitriles
DE3626058A1 (de) * 1986-08-01 1988-02-11 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
DE3776880D1 (de) * 1986-11-21 1992-04-02 Ciba Geigy Ag Neue substituierte alkandiphosphonsaeuren.

Also Published As

Publication number Publication date
US20060069067A1 (en) 2006-03-30
EP1534265A1 (de) 2005-06-01
WO2004012728A1 (en) 2004-02-12
EP1534265B1 (de) 2006-11-22
CN100593401C (zh) 2010-03-10
BR0313081A (pt) 2005-07-12
DE60309887T2 (de) 2007-05-16
CA2494345C (en) 2011-11-29
AU2003250190A1 (en) 2004-02-23
PT1534265E (pt) 2007-02-28
ES2276119T3 (es) 2007-06-16
ATE345790T1 (de) 2006-12-15
CN1671371A (zh) 2005-09-21
CA2494345A1 (en) 2004-02-12
JP2011057706A (ja) 2011-03-24

Similar Documents

Publication Publication Date Title
DE60309887D1 (de) Kombination von einem aromatasehemmer mit einem bisphosphonat
MX2010006519A (es) Metodo para tratar una fractura de hueso con anticuerpos anti-esclerostina.
DE60030889D1 (de) Verwendung von egfr tyrosine kinase hemmern zur behandlung von brustkrebs
MXPA06001110A (es) Uso de una combinacion de un inhibidor de la cinasa del receptor del factor de crecimiento epidermico y agentes citotoxicos para el tratamiento e inhibicion del cancer.
DE60236413D1 (de) Inhibitoren von hmgb1 zur behandlung von gewebekrankheiten
WO2004043374A3 (en) Methods and compositions for treating cancer using proteasome inhibitors
UA94899C2 (ru) Фиксированное дозирование антител к her
WO2022271810A3 (en) Bicyclic peptidyl pan-ras inhibitors
BR0307629A (pt) Métodos e composições para tratar condições hiperproliferativas
HK1080733A1 (en) Pharmaceutical composition for use for the treatment of malignancies comprising in combination a bisphosphonates, a cox-2 inhibitor and a taxol
BR0314081A (pt) Terapia de combinação compreendendo um bisfosfonato e um inibidor de hmg-coa redutase
EA200501456A1 (ru) Торий- 227 для применения в радиотерапии заболевания мягких тканей
WO2002074756A3 (de) Urokinase-inhibitoren
MXPA05013975A (es) Tratamiento de enfermedades asociadas con amiloide y epileptogenesis.
MXPA01007031A (es) Metodo para tratar enfermedades acrdiacas cronicas.
EA200600989A1 (ru) Применение габоксадола для лечения бессонницы
TNSN06147A1 (en) Use of cathepsin k inhibitors for treating of severe bone loss diseases
DE60334289D1 (de) Dithiolopyrrolon-derivate zur behandlung von proliferativen störungen
HUP9903685A2 (hu) Olanzapin alkalmazása túlzott agresszivitás kezelésére szolgáló gyógyszerkészítmények előállítására
TW200512183A (en) 2-alkylidene-19-nor-vitamin d derivatives for the treatment of frailty, muscle damage or sarcopenia
TW200519078A (en) 2-alkylidene-19-nor-vitamin d derivatives for the treatment of a second hip fracture
DE60108775D1 (de) Methode zur behandlung von schlaganfall
MXPA05010216A (es) Uso de ritonavir para el tratamiento de hiperbilirrubinemia no conjugada.
TW200511998A (en) 2-alkylidene-19-nor-vitamin d derivatives for the treatment of anorexia or low bone mass in females exhibiting aggressive athletic behavior
BR0315376A (pt) Combinações de benzotiadiazóis e inibidores de cox-2 para o tratamento de dor

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: KROHER, STROBEL RECHTS- UND PATENTANWAELTE, 80336

8328 Change in the person/name/address of the agent

Representative=s name: DR. SCHOEN & PARTNER, 80336 MUENCHEN